Japan Opens Arms Export Floodgates: New Policy Draws Global Defense Interest 
Goldman Sachs FICC Revenue Falls 10% Amid Iran War Market Volatility 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
TSMC Posts Record Q1 Profit Fueled by AI Chip Demand 
Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Anthropic Nears $800 Billion Valuation as Investor Confidence Surges 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
CATL Stock Hits Record High After Q1 2025 Earnings Surge 
Sam Altman Moves to Dismiss Punitive Damages in Sister's Sexual Abuse Lawsuit 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, June 01, 2017 -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it will present a corporate overview and host investor meetings during the Jefferies Healthcare Conference, held in New York City, from June 6 - 9, 2017.
Matt Kapusta, chief executive officer, will present on Friday, June 9, 2017 at 8:00 am EDT. The live webcast of the presentation can be accessed through the link displayed in the Investor Section of uniQure website at http://uniqure.com/investors-newsroom/events-presentations.php. A replay of the webcast will be available within 24 hours following the event, and will remain available for at least two weeks.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with hemophilia, Huntington’s disease and cardiovascular diseases. www.uniQure.com
uniQure Contacts: Maria E. Cantor Direct: 339-970-7536 Mobile: 617-680-9452 [email protected] Tom Malone Direct: 339-970-7558 Mobile: 339-223-8541 [email protected] Eva M. Mulder Direct: +31 20 240 6103 Mobile: +31 6 52 33 15 79 [email protected]
